Evidence map›Paper›PMID 32533071›Full record

SynthesisThe Journal of antibiotics2020

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.

Fatemeh Heidary, Reza Gharebaghi

5 registry-linked trialsOpen access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Journal of antibiotics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 146 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 6 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04602507 phase2terminatednot on this map

Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial

TypeinterventionalSponsorCES UniversityRan2020 to 2021Enrolled75ConditionsCovid19, Severe Acute Respiratory SyndromeArmsIvermectin, Placebo
NCT04646109 phase3completednot on this map

The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management

TypeinterventionalSponsorAfyonkarahisar Health Sciences UniversityRan2020 to 2020Enrolled66ConditionsCOVID-19ArmsIvermectin
NCT04836299 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Therapeutic Safety of Ivermectin Versus Placebo Associated With Standard of Care Treatment in the Early Phase of Coronavirus Infection (COVID19).

TypeinterventionalSponsorUniversidad Mayor de San SimónRan2021 to 2021Enrolled90ConditionsCovid19ArmsIvermectin, Placebo
NCT04891250 phase4withdrawnnot on this mapstarted 2021, after this paper: background citation

The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19

TypeinterventionalSponsorCentre for Infectious Disease Research in ZambiaRan2021 to 2022Enrolled0ConditionsSARS-CoV-2, IvermectinArmsIvermectin, Prophylaxis
NCT05269030 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

The Potential Therapeutic Effect of Ivermectin Nasal Drops in the Treatment of Post COVID-19 Parosmia

TypeinterventionalSponsorMenoufia UniversityRan2022 to 2023Enrolled60ConditionsParosmiaArmsIvermectin Topical, Budesonide Nasal
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 6 syntheses or guidelines pooled it, 452 citations in OpenAlex.

  1. Pooled it
  2. Is Ivermectin Effective in Treating COVID-19?Frontiers in pharmacology · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2021
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Fatemeh HeidaryHead of Ophthalmology Division, Taleghani Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. drfatemehheidari@yahoo.com.
Reza GharebaghiKish International Campus, University of Tehran, Tehran, Iran. drgharebaghi@yahoo.com.
Ahvaz Jundishapur University of Medical Sciences · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.

Indexed as

AnimalsAntiviral AgentsBetacoronavirusCell LineDisease Models, AnimalDNA VirusesGlobal HealthHumansIvermectinMolecular StructureRNA VirusesSARS-CoV-2Antiviral AgentsIvermectin

Identifiers

PMID32533071
PMCPMC7290143
OpenAlexW3035026987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.